The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and
Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by
the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the
treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Erlotinib 150mg and bexarotene 400mg/m2 will be administered orally for 7-9 days prior to
thoracotomy. Plasma samples will be collected on the day before surgery and along with
tissue samples on the day of the thoracotomy. Analyses will be done on the resected
specimen and it will be compared to the pre-study diagnostic specimen.
- Resectable stage I or II non-small-cell lung cancer
- Prior tissue biopsy (not cytology) available for research analysis
- Adequate hepatic and renal function
- Prior chemotherapy or radiotherapy